Antoinette, who has type 1 diabetes, is recommending Novolog® rapid-acting insulin

NovoLog® significantly reduces postprandial glucose (PPG) levels

NovoLog® demonstrated PPG control when used in a pump1

The graph below shows plasma glucose profiles in patients with type 1 diabetes who were assigned to NovoLog® or insulin lispro in pump use. (Another arm of the study used buffered human insulin, which is no longer available in the United States. Those results are not shown here.) After 16 weeks, NovoLog®provided better mean glucose levels after dinner than insulin lispro.

 

Mean PPG levels after dinner versus insulin lispro in patients with type 1 diabetes1

chart comparing pre and post meal blood glucose values of NovoLog® and insulin lispro


A 16-week, open-label, randomized, parallel-group study enrolling 146 patients with type 1 diabetes for at least 12 months. Patients were randomized to receive NovoLog® (n=59), insulin lispro (n=28), or buffered regular insulin (n=59) as part of CSII therapy. Buffered regular insulin is no longer manufactured in the United States.

Adapted from Bode et al, 2002.1


 

This study also examined rates of hypoglycemia vs insulin lispro


 

Mean PPG levels after lunch for NovoLog®, insulin glulisine, and insulin lispro.2

7-point self-monitored plasma glucose in the last week2

Chart comparing glucose levels after lunch for NovoLog® insulin gluisine and insulin lispro


AB=after breakfast; AD=after dinner; AL=after lunch; BD=before dinner;
BL=before lunch; FG=fasting glucose; N=night at 3 am

A 39-week, randomized, controlled, multinational, open-label, 3-way crossover study enrolling 256 adult patients with type 1 diabetes assigned to 1 of 3 treatment groups (glulisine–NovoLog®–lispro; NovoLog®–lispro–glulisine; lispro–glulisine– NovoLog®) and then “crossed over” (13 weeks per each intervention).

Adapted from van Bon et al, 2011.2

  • Significantly lower mean rate of symptomatic hypoglycemica events per patient per year (NovoLog® 65.0, insulin glulisine 73.8) (P=0.008)
  • Rate of major hypoglycemia was not different among the 3 insulin groups

<70mg/dL with symptoms.

 

This study also examined rates of hypoglycemia vs insulin glulisine


 



 

NovoLog® provides significantly lower mean PPG levels after 3 meals vs human insulin3,4

In a 6-month study of patients with type 1 diabetes who added mealtime injections of either NovoLog® or regular human insulin to a basal regimen with NPH human insulin, NovoLog® provided significantly lower PPG levels than regular human insulin — a difference of 30 mg/dL.

Lower mean PPG levels after 3 meals vs human insulin

A 6-month, randomized, open-label, parallel-group study enrolling 882 patients who had type 1 diabetes for at least 18 months. Patients taking NPH insulin were randomized to either NovoLog® or regular human insulin as part of basal-bolus therapy. There was a 6-month optional extension of this trial.3

Adapted from Raskin et al, 2002.3
 


 


Get insights from experts

Jaime Davidson, MD, FACP, MACE talks about the importance of PPG levels as a guide in treatment.

Selected Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased.

NovoLog® (insulin aspart injection) 100 U/mL Indications and Usage

NovoLog® (insulin aspart injection) 100 U/mL is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. 

Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. 
  • Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. 
  • To avoid medication errors and accidental mix-ups between NovoLog® and other insulin products, instruct patients to always check the insulin label before injection. 
  • Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog®
  • As with all insulins, NovoLog® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death.  Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered. 
  • Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. 

NovoLog® continuous subcutaneous infusion route (insulin pump): Do not mix NovoLog® with any other insulin or diluent. 

Adverse Reactions

  • Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. 

Use in Specific Populations

  • NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age. 
  • Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment. These patients may require more frequent blood glucose monitoring and dose adjustments. 

Please click here for Prescribing Information.

 

References

  1. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 2002;25(3):439-444.
  2. van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2011;13(6):607-614.
  3. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23(5):583-588.
  4. Data on file. Novo Nordisk, Inc., Plainsboro, NJ.